Imprimis Pharmaceuticals Inc. (IMMY) Stock Price Down 3.8%
Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) traded down 3.8% on Tuesday . The stock traded as low as $3.75 and last traded at $3.75, with a volume of 52,154 shares trading hands. The stock had previously closed at $3.90.
Separately, Zacks Investment Research upgraded Imprimis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 1st.
The stock’s market cap is $49.89 million. The firm’s 50 day moving average is $3.85 and its 200-day moving average is $4.01.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last issued its quarterly earnings data on Monday, August 15th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter. The business earned $4.90 million during the quarter, compared to analyst estimates of $4.53 million. Equities research analysts predict that Imprimis Pharmaceuticals Inc. will post ($0.94) EPS for the current fiscal year.
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.